| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Comprehensive disease testing
In addition to accessing our clinically available tests, BioPharma Diagnostics partners can access oncological testing for clinical trials and be among the first to use up-and-coming tests currently in development.
The latest
Aiming to advance understanding of hard-to-predict gastroenteropancreatic neuroendocrine tumors (GEP-NETs), Thermo Fisher Scientific joined forces with Mayo Clinic and BioPharma Diagnostics to validate and gain U.S. regulatory clearance of a novel, automated assay aimed at detecting a biomarker associated with the progressive disease.
Neuro-oncology is a complex field undergoing rapid changes with the advancement and evolution of sophisticated genetic testing. Evidence continues to grow in support of broad molecular and cytogenetic analysis for patients with brain tumors.
This week’s Research Roundup highlights how the EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis.
This week’s Research Roundup highlights the diagnostic accuracy of echocardiography and intraoperative surgical inspection of the unicuspid aortic valve.
Genetic alterations in low-risk prostate cancer diagnosed by needle biopsy can identify men that harbor higher-risk cancer in their prostate glands, Mayo Clinic has discovered.
Researchers at the Mayo Clinic Center for Individualized Medicine have discovered that large chromosomal rearrangements present in mesothelioma could make it possible to understand which patients are likely respond better to immunotherapy.
This week’s Research Roundup highlights neoantigenic potential of complex chromosomal rearrangements in mesothelioma.
Researchers at Mayo Clinic have identified three specific gene types that account for a known two- to three-fold increase in myeloma diagnoses among African-Americans. Researchers also demonstrated the ability to study race and racial admixture more accurately using DNA analysis. The findings were published today in Blood Cancer Journal.
This week’s Research Roundup highlights carcinoid heart disease in patients with bronchopulmonary carcinoid.
This week’s Research Roundup highlights the risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics.
This week’s Research Roundup highlights hepatocellular carcinoma detection by plasma methylated DNA through a discovery, phase I pilot, and phase II clinical validation.
This week’s Research Roundup highlights biphenotypic acute leukemia versus myeloid antigen-positive ALL: Clinical relevance of WHO criteria for mixed phenotype acute leukemia.
Clinical studies at the Mayo Clinic have shown that this broad, but tumor-specific, genetic analysis has significant, and sometimes unexpected, clinical impact. The following case studies highlight the importance and clinical utility of these assays in diagnosis, prognosis, and therapy selection.